Market
What will be Trodelvy's market position in ES-SCLC treatment by end of 2025?
2
Resolution / Starting Odds
Leading • 25%
Second • 25%
Third • 25%
Lower • 25%
Market analysis reports from reputable industry analysts
Story
FDA Grants Breakthrough Therapy Designation to Trodelvy for ES-SCLC Treatment
Dec 18, 2024, 12:06 PM
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for the second-line treatment of extensive-stage small cell lung cancer (ES-SCLC). This designation is intended to expedite the development and review of drugs that demonstrate substantial improvement over existing therapies for serious or life-threatening conditions. Trodelvy, developed by Gilead Sciences, has shown promise in addressing the needs of patients with ES-SCLC who have limited treatment options. The FDA's decision highlights the potential of Trodelvy to improve outcomes for this patient population.
View original story
Similar markets
European Union • 25%
Other • 25%
Canada • 25%
Japan • 25%
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
11-15 trials • 25%
More than 15 trials • 25%
0-5 trials • 25%
6-10 trials • 25%
No • 50%
Yes • 50%
Increase by 5-10% • 25%
Increase by more than 10% • 25%
Increase by less than 5% • 25%
No significant change or decrease • 25%
40-60% • 25%
Less than 20% • 25%
20-40% • 25%
More than 60% • 25%
10% to 20% • 25%
Less than 10% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Approved in EU • 25%
Approved in US • 25%
Approved in both US and EU • 25%
Not approved in US or EU • 25%